3月10日，Genmab宣布强生决定不再行使HexaBody-CD38（GEN3014）的全球开发和商业化选择权。消息出来后，Genmab股价下跌7.8%。 截图来源：企业官网 ...

为解决皮肤 T 细胞淋巴瘤（CTCL）治疗难题，研究人员探究 CD38 作用及联合疗法，发现联合治疗可提升疗效。 皮肤 T 细胞淋巴瘤（Cutaneous T-Cell Lymphoma，CTCL）是一种让人头疼的非霍奇金淋巴瘤，它专门 “攻击” 皮肤里的恶性 T 细胞。得了这种病，患者皮肤状况 ...

is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action ...

一、CD38单抗市场竞争分析 1. 达雷妥尤 ... 3-5分钟皮下给药将大幅缩短MM和AL患者的治疗时间，让中国的浆细胞疾病的治疗实现了和国际接轨。

Sarclisa is a CD38 monoclonal antibody that targets the CD38 receptor on MM cells, inducing apoptosis and immunomodulatory activity. In December 2023, Sanofi reported that its Phase III IMROZ ...

(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

MM continues to be a therapeutically challenging ... but not limited to, mAbs specific for CD38, CS1, CD40, CD74, CD70, HM1.24, IL-6 and B2MG directed against a number of potential targets for ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...